A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ezetimibe (Zetia)

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyper....

First FDA approval2017-06-12
Generic availableYes · 12 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$322.7M in CY2024 Part D spend13.9M claims · 4.9M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.073/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.073
Across all dosage forms in distribution.
Highest NADAC
$0.073
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Ezetimibe used for?

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyper....

Is there a generic for Ezetimibe?

Yes. 12 ANDAs filed at FDA, 12 generic manufacturers currently shipping.

How much does my plan pay for Ezetimibe?

Across 329 Part D plans, Ezetimibe averages $0.073/unit (NADAC). Lowest available: $0.073/unit. Highest in distribution: $0.073/unit.

Is Ezetimibe on the FDA shortage list?

Ezetimibe has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.